` PHARM (Pharming Group NV) vs DAX Index Comparison - Alpha Spread

PHARM
vs
DAX Index

Over the past 12 months, PHARM has underperformed DAX Index, delivering a return of -30% compared to the DAX Index's 13% growth.

Stocks Performance
PHARM vs DAX Index

Loading

Performance Gap
PHARM vs DAX Index

Loading
PHARM
DAX Index
Difference

Performance By Year
PHARM vs DAX Index

Loading
PHARM
DAX Index
Add Stock

Competitors Performance
Pharming Group NV vs Peers

DAX Index
PHARM
ABBV
AMGN
GILD
VRTX
Add Stock

Pharming Group NV
Glance View

Market Cap
468.1m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.101 EUR
Undervaluation 38%
Intrinsic Value
Price
Back to Top